News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Scancell: DNA ImmunoBody Patent Granted In United States


6/6/2014 10:47:58 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

06 June 2014 -- Scancell Holdings plc (‘Scancell’ or the ‘Company’), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that a patent for its DNA ImmunoBody® technology has been granted in the United States.

The patent, number 8,742,088, has been granted by The United States Patent and Trademark Office (USPTO) and covers Scancell’s DNA ImmunoBody® platform technology. This patent is key for the protection of the Company’s pipeline of ImmunoBody® vaccines and follows the grant of counterparts in Australia, China and Japan.

Scancell’s protein ImmunoBody® patent has already been granted in Australia, Canada, Europe, Japan and the United States.

Dr. Richard Goodfellow, Joint Chief Executive of Scancell, commented:

“We are delighted to have further strengthened our IP portfolio around our proprietary ImmunoBody® platform technology. The United States is a key market for us and this, alongside the recent positive results from the Phase 1/2 trial for our SCIB1 ImmunoBody® in melanoma, demonstrates the strong progress Scancell is making. We look forward to continuing development of our ImmunoBody® platform and advancing our SCIB1 clinical trial, bringing patients one step closer to a new treatment for melanoma.”

For Further Information:

Dr Richard Goodfellow, Joint CEO
Professor Lindy Durrant, Joint CEO Scancell Holdings Plc
Scancell Holdings Plc + 44 (0) 20 3727 1000

Camilla Hume/Stephen Keys Cenkos Securities + 44 (0) 20 7397 8900

Mo Noonan/Simon Conway FTI Consulting + 44 (0) 20 3727 1000

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1 has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

Natalie Garland-Collins
Senior Consultant, Strategic Communications
FTI Consulting
+44 (0)20 3727 1187
Natalie.Garland-Collins@fticonsulting.com

200 Aldersgate | Aldersgate Street
London, EC1A 4HD
www.fticonsulting.com
@FTI_EMEA

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES